How far are we from a viable COVID-19 treatment? Worldwide, over 178,000 people have died so far, with confirmed cases numbering more than …
In a research report sent to investors today, MLV analyst George Zavoico maintained a Buy rating on Pluristem Therapeutics (NASDAQ:PSTI) with a $6.00 …
In a research report issued this morning, H.C.
In a research report published Monday, Maxim analyst Jason Kolbert maintained a Buy rating on Pluristem Therapeutics (NASDAQ:PSTI) with an $8.00 price target, …
In a research note published yesterday, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Pluristem Therapeutics (NASDAQ:PSTI) and an $8 price …
